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2ABBREVIATIONS USED IN THIS THESIS
ME Crude mushroom extract
BME Mushroom extract prepared with boiling
BF BME after ultrafiltration
BFR BF after deionization
Fl BF after fractionation with Sephadex G-25
BP Arterial blood pressure
MW Molecular weight
GFR Glomerular filtration rate
RPF Renal plasma flow
FF Filtration fraction
PAH Para-aminohippurate
ARF Acute renal failure
SEM Standard error of mean
t-test Student t-test for paired observations performed
by statistical package ABSTAT, Release 3.04,
Anderson-Bell
NS Not significant different from the initial value
3ABSTRACT
Hypotensive effect in a dose dependent manner is observed when
an aqueous extract of the phoenix mushroom Pleurotus sajor-caju is
infused into anaesthetized rats. The action of the extract is
believed to be vasodilatation leading to a decrease in total
peripheral resistance. The active ingredient in the extract is
believed to be a peptide, which is heat stable, partially
inactivated.by trypsin digestion and with a molecular weight between
1,500-5,000. Its hypotensive action is not mediated through alpha-
adrenoceptor, beta-adrenoceptor, muscarinic and histamine receptors.
However, both the magnitude and duration of hypotensive action of
the extract are reduced in captopril pretreated rats. The pressor
effect of angiotensin I is impaired in rats pretreated with the
mushroom extract. These observations suggest that the hypotensive
action of the mushroom extract is mediated through the inhibition of
angiotensin converting enzyme.
The purified fraction of the mushroom extract (Fl) is not only
capable of lowering the arterial blood pressure but also the
glomerular filtration rate (GFR) of rats. The fall of GFR is not
related to the change in the systemic blood pressure. Renal
hemodynamic studies indicate that the reduction of GFR is not due
to the fall of renal plasma flow (RPF), and there is no apparent
gross tubular damage after the administration of the extract. The
decrease in GFR is progressive and lasts for at least three hours
after administration. With the same dose of the same extract, the
hypotensive action only lasts for about 30 minutes. Continuous
4infusion of captopril increases both the GFR and RPF of rats and
totally abolishes the renal effects of Fl. The data suggest that
there are two possible mechanisms for the renal action of the
extract. It may induce a change in glomerular permeability, or it
may induce a pressor effect on afferent arterioles and a depressor
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With technological advancement during the past few decades, the
cultivation of edible mushrooms has spread all over the world. The
total production of cultivated mushrooms has been estimated to be
1,357 thousand tonnes in 1981 (1). Since some mushrooms can be
cultivated on-agricultural and industrial wastes, it provides an
important source of food protein. through recycling of such wastes.
The five most important cultivated mushrooms are the white mushroom
(Agaricus bisporus), the black forest mushroom (Lentinus edodes),
the winter mushroom (Flammulina velutipes), the straw mushroom
(Volvariella volvacea), and the oyster mushrooms (Pleurotus spp.).
From the earliest time, mushrooms have been treated as a
special kind of food. The Greeks regarded mushrooms as providing
strength for warriors in battle. The Romans regarded mushrooms as
the 'Food of the Gods,' which was served only on special
occasions. The Chinese recognized mushrooms as a tonic element for
longevity. Although there are many folklores in various parts of the
world describing the medical benefits of mushroom consumption, their
active principles have not been extensively investigated. Very
often, verifications of folklores may lead to discovery and
isolation of the active ingredients involved. One of the examples is
calcacin, a possible antitumor agent isolated from the giant
2puffball Calcatia gigantea (2). In this introduction, only those
edible mushrooms with potential medical applications will be
mentioned. Extensive reviews for the biological activities of edible
and higher fungi can be found elsewhere (3,4,5).
1.2 Antitumor effects
From Ikekawa's study (6), edible mushrooms with antitumor
activity included Lentinus edodes, Flammulina velutipes, Pleurotus
ostreatus, Pleurotus spodoleucus, Pholiota nameko, Armillaria
caligata and Auricularia auricula. There are a variety of chemicals
derived from edible mushrooms which show antitumor activities. For
example: some polysaccharides from Lentinus edodes (6,7), Pleurotus
ostreatus (8) and Flammulina velutipes (9) the basic protein from
Flammulina velutipes (10) the acidic protein from Poria corticola
(11,12) the basic mucoprotein from Calvatia gigantea (2,13);
triterpenoid from Poria obliqua (14) and quinoid from Agaricus
bisporus (15).
Amongst the various antitumor agents from mushrooms, lentinan,
a polysaccharide from Lentinus edodes, has received most of the
attention. Lentinan suppresses the growth of transplanted Sacroma-
180 in mice (7). The antitumor effect of lentinan is lost in
neonatally thymectomized mice, and decreases considerably with
adminstration of antilymphocyte serum (16). It is suggested that the
inhibitory effect of lentinan is not due to its cytotoxicity on
tumour cells, but.rather due to a cell-mediated action. The possible
3role of lentinan in the cell-mediated action is to serve as a T-
lymphocyte adjuvant in potentiating the immune response (17). The
major action is mediated through a cytostatic action of activated
macrophages on tumor cells. Fujii et al. (18) isolated and
characterized a new antitumor polysaccharide KS-2 from the culture
mycelia of Lentinus edodes. KS-2 is mainly composed of o.-linked
mannose and contains a small amount of peptides, and could suppress
the growth of Ehrlich tumors as well as Sacroma-180 tumors in mice.
More recently, Sugano et al. (19) also detected anticarcinogenic
activities in extracts from culture medium of Lentinus edodes
mycelia.
1.3 Antiviral effects
Cochran was first to report that antiviral substances were
present in mushroom (20). In a screening test for activity against
poliomyelitis in mice, four species of edible mushroom were shown to
provide significant protection against infection. These included
Boletus frostii, Calvatia gigantea, Chlorophyllum esculentum, and
Agaricus campestris (21). Other studies also demonstrated that
extracts from Boletus edulis, Calvatia gigantea, Suillus luteus, and
Lentinus edodes showed protection against influenza both in vitro
and in vivo (22). The antiviral effect is believed to be mediated
through the induction of interferon on the host as demonstrated with
an extract from donko mushroom (Cortinelluf shiitake) in mice (23).
Similar to the antitumor studies, Lentinus edodes has received most
of the attention in elucidating the active principles for antiviral
activity. Suzuki. et al. (24) confirmed that the interferon
4inducing activity is due to the double-stranded RNA from the extract
of Lentinus edodes. The origin of these double-stranded RNA was
believed to be derived from the virus-like particles attached on the
spore and fruit body of mushroom (25,26). The virus-like particle is
also present in several other mushrooms and is not unique to
Lentinus edodes (27). However, double-stranded RNAs from various
sources are intrinsically toxic by causing thymic atrophy and
lymphocyte transformation when given intravenously (28). Thus their
potential medical applications are hindered. Furthermore, extracts
from these virus-like particles were reported to be anticarcinogenic
but the effects were not related to their interferon inducing
activities (29). Their antitumour activity was believed to be due to
the cytotoxic action of the double-stranded RNA (30).
1.4 Anti-atherosclerosis
Fibrocellular proliferation and cholesterol accumulation are
the two dominant features of the developing atherosclerotic plaque.
Both represent the expanding components of the plaque which intrude
upon the arterial lumen, resulting in occlusion of vessel. Different
theories for the pathogenesis of atherosclerosis have been proposed.
The lipogenic theory (31) is based upon the strong relationship
between plasma lipoprotein alterations and atherosclerosis in human
and experiment animals, but there is still ambiguity as to how
lipids and lipoproteins may stimulate cell growth in the arterial
wall. The response-to-injury theory (32) is based upon the discovery
of smooth muscle growth factors derived from platelets and
5macrophages during arterial injury. However, the response-to-injury
theory provides little explanation for the various forms and
locations of cholesterol accumulation.
Kaneda et al. (33) was the first group to report that edible
mushrooms possessed hypocholesterolemic activity. The plasma level
of cholesterol was significantly lowered when Lentinus edodes was
chronically fed to rats Other edible mushrooms with
hypocholesterolemic activity included Agaricus bisporus, Auricularia
polytricha and Flammulina velutipes (34). The active hypolipidemic
principle in. Lentinus edodes has been identified as eritadenine,
2(R),3(R)-dihydroxy-4-(9-adeny)-butyric acid (35,36,37). It has been
demonstrated that eritadenine lowers plasma cholesterol in rat as
rapidly as three hours after administration and the effect lasts as
long as one year on chronic feeding (38). The action of eritadenine
was attributed to an accelerated tissue uptake of plasma cholesterol
(39). In addition, the isoamyl ester of eritadenine has been
reported to inhibit protein kinase and cyclic adenosine
monophasphate phosphodiesterase (40). The-hypocholesterolemic effect
of Lentinus edodes was also observed in human subjects after chronic
feeding (41).
During hypercholesterolemia, permeability of endothelium to
'plasma macromolecules is increased (42). Increased macromolecular
permeability may stimulate the growth of underlying smooth muscle
and thus lead to fibrocellular proliferation. The specific factors
involved are still not very clear but the Low Density Lipoprotein
(plasma carrier of cholesterol) seems to be a likely candidate.
6Platelets derived from hypercholesterolemic subjects aggregate more
readily than normal individuals (43). An antiplatelet substance was
characterized from the aqueous extract of Auricularia polytricha,
which could inhibit platelet aggregation (44). This substance was
later identified to be adenosine (45). Release of platelet-derived
growth factor stimulates the proliferation of smooth muscle cells
and thus attributes to the pathogenesis of atherosclerosis.
Therefore, the effect of anti-platelet aggregation and
hypocholesterolemia, of edible mushrooms both are beneficial to
hypercholesterolemic patients in reducing the risk of
atherosclerosis. Chronic consumptions of edible mushrooms in normal
subject may be regarded as a prophylaxis against atherosclerosis.
1.5 Other biological activities
In the present study, attempts are made to verify the folklore
that mushroom consumption can lower the arterial blood pressure and
are beneficial to hypertensive patient (46). Hypertension is a
highly complicated disorder. Eighty percent of all hypertensive
patients do not have a well defined cause. Despite the complexity in
pathogenesis, hypertension can be visualized as the consequence of
(i) overfilling of the vascular bed and (ii) inappropriate
contraction of the vascular bed (47).
A cultivated edible oyster mushroom (phoenix mushroom),
Pleurotus saja-caju, is chosen as the subject of study. Pleurotus
spp., along with Lentinus edodes and Volvariella volvacea, has
7gainea prominence as a type or eaible musnroom in eastern countries
in recent years (48). The approach of this study was firstly to
prepare an aqueous extract of the mushroom. The extract was then
given intravenously into rats to determine whether it was vasoactive
or not. It was followed by efforts to differentiate the action of
impurity like electrolytes from the possible active ingredients
involved. Since kidney was mainly responsible for the regulation of
body fluid which was closely related to hypertension,* Glomerular
Filtration Rate (GFR) was chosen as one of the renal physiological
parameters in studying the effect of mushroom extract. The
vasoactivity and effect on GFR should then be employed as criteria
to search and identify the active ingredients involved during the
subsequent steps of purification. Finally, attempts would be given
to try out their pharmacological basis of action by using different
pharmacological blockers according to possible sites of
antihypertensive action, while other renal hemodynamic parameters
would also be employed to further characterize the renal effects of
the purified fraction.
8CHAPTER II
PREPARATION AND CHARACTERIZATION OF MUSHROOM EXTRACT
2.1 Materials and Methods
2.1.1 Preparartion of the Mushroom Extract (ME)
The phoenix mushroom, Pleurotus sajor-caju, was-cultivated in
the mushroom cultivation room of the Biology Department, Chinese
University of Hong Kong. The procedures for cultivation were
described elsewhere (49). Since mushrooms were very often consumed
in the form of soup, the aqueous extract of this mushroom was
prepared for examination. Pleurotus sajor-caju was harvested right
after the development of the fruit bodies. 80 g of the whole
mushroom was mixed with 250 ml of cold distilled water and
homogenized in a blender for 5 minutes. The solution was shaken at
100 rpm for 12 hours on a rotatory shaker in the cold room, and then
centrifuged at 15,000 x g in a Beckman J2-21 refrigerated centrifuge
for one hour. The supernatant was then lyophilized. The product
obtained was the crude aqueous extract of Pleurotus sajor-caju (ME)
used in the subsequent studies.
2.1.2 Effect of ME on arterial blood pressure of rat
Male Spraque-Dawley rats with body weights between 350 to 400 g
were anaesthetized with sodium.pentabarbitol (60 mg/kg). The left
carotid artery and right jugular vein were cannulated (PE-50
9polyethylene catheter) for arterial blood pressure measurement and
fluid infusion respectively. The blood pressure was monitored with a
Lectromed MX 216 recorder via a pressure transducer (Gould P23).
Rats were nnnPsthetized throughout the ueriod of investigation.
100 mg of ME was dissolved in 1 ml distilled water and
subsequent dilutions with 0.9% saline were made from this stock
solution. After a 30 minute equilibration, one ml of 0.9% saline was
infused in- one minute with a compact infusion pump (Harvard
Apparatus) into each freshly prepared rat to demonstrate that
infusion of such volume had minimal effect on blood pressure. Five
minutes later, it was followed by a dose of ME in exactly the same
volume and time. In order to avoid tachyphylaxis, each rat was
tested with a single dose only. A typical dose of 25 mg was chosen
for subsequent studies. Changes in systolic, diastolic and mean
arterial blood pressure were determined by taking the largest
decrease within the period of 5 to 10 minutes after ME infusion.
2.1.3 Effect of cations content in the ME
To determine the major cation composition of Pleurotus sajor-
caju, 25 mg of ME was dissolved in 1 ml of distilled water. The
sodium and potassium concentrations were determined by a Corning 435
flame photometer, while calcium and magnesium concentrations were
measured by a Varian AA-1475 atomic absorption spectrophotometer.
The osmolarity of the same solution was determined by freezing point
depression. An aqueous solution was reconstituted with NaCl, KC1,
CaC12. 2H20, and MgSO4. 7H20 having the same cationic compositions
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equivalent to the various doses of ME. The simulated electrolyte
solutions were then administered through the intravenous route in
exactly the same way as ME infusion. The systolic, diastolic and
mean arterial blood pressure were studied as described above.
2.1.4 Effect of ME in Langendorff isolated perfused heart
Male Spraque-Dawley rats (350-400 g) were anaesthetized by
ether and the heart was excised rapidly after thoracotomy. The
isolated heart was immediately suspended and squeezed in an ice-cold
oxygenated modified Krebs-Ringer solution. Heparin was added to the
Krebs-Ringer to prevent blood coagulation. Any accessory tissues
attached on the heart were removed and the aorta was cut below the
point where it divided. The out aortic stump was secured with
ligature to a grooved cannula for retrograde perfusion of the
coronary circulation. Care was taken to avoid air bubbles being
trapped in the aorta. A diagram of the apparatus was shown in Figure 1.
Perfusion began by delivering perfusate to the heart from a
wash out reservoir at a rate of 6-8 ml/min. The heart was stabilized
for at least 20 min before any injection of ME was made. The
injection was via a cannula inserted into the aorta. The change in
heart rate and contractile force of the isolated heart was detected
by a force transducer (Gould UC2) coupled to a string, which was
attached on the vertex of the isolated heart with a small clamp. The
transducer was connected to a Lectromed MX 216 recorder for
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recording. ME was dissolved in Krebs-Ringer solution (25 mg/ml) for
administration. The injection volume was 0.2 ml delivered over 5
seconds. Same volume of Krebs-Ringer solution was injected prior to
ME injection. All solutions for injections were incubated at 37°C.
The modified Krebs-Ringer solution, pH 7.4, was equilibrated
with 95% oxygen: 5% carbon dioxide at 37°C. Final concentrations of
the salts in this medium (in mM) were: NaCl, 118.1; KC1, 4.7;
MgSO4 .7H20, 1.2; NaHC03, 25; glucose, 11; CaC12.2H20, 25.
2.1.5 Effect of ME on Glomerular Filtration Rate (GFR)
Male Spraque-Dawley rats (350-400 g) were anaesthetized with
sodium pentobarbital (60 mg/kg) and polyethylene catheters (PE-50)
were placed in the left carotid artery and in the right jugular and
femoral vein. The bladder catheter consisted of polyethylene tubing
(PE-240) with a flanged end placed in the bladder. Clearance of
tritiated-inulin(Amersham) was measured as an indicator of GFR
(50).
A priming dose of tritiated-inulin (5uCi) in 0.75 ml normal
saline was injected via the jugular vein and followed by a
maintenance dose (0.082 uCi/min) infused at a rate of 0.078 ml/min.
Urine samples were collected at intervals of 45 minutes via the
bladder catheter. Arterial blood samples were collected at the
midpoint of each period. After two control periods, one ml of ME
solution with a concentration of 25 mg/ml was infused via the
femoral vein over.15 minutes. Saline instead of ME was infused in
12
the control. Arterial blood pressure was measured throughout the
experiment except during blood sampling. Tritiated-inulin
concentrations of plasma and urine were then determined by liquid
scintillation counting (Beckman LS 1801 scintillation counter).
2.2. Results
The yield of ME after lyophilization was 3.43+ 0.39% by weight
of the original raw material. The cations composition of 25 mg of ME







*values are expressed as mean+ SEE
with an osmolarity of 300+ 2 mOsm which is close to isotonicity. An
artificial reconstituted electrolyte solution with the same
composition as 6.25 mg/ml (A), 12.5 mg/ml (2A), 25 mg/ml (4A), 50
mg/ml (8A), and 100 mg/ml (16A) of ME was infused into the rats and
these electrolyte solutions caused a transient elevation of
arterial blood pressure (Fig. 2) which lasted no more than 3
minutes.
Different doses of ME were infused into freshly prepared rats
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and produced a dose dependent depressor effect on arterial blood
pressure. With each individual dose of ME the changes in systolic,
diastolic and mean arterial blood pressure were not significantly
different from each other (Fig. 3). The effect of ME (25 mg) on





values are expressed as mean+ SEM (n=5)
p O.05
Except in the first minute after ME infusion, heart rate was not
significantly different from the control in all the rats (p0.05).
When saline was infused prior to ME, blood pressure was not
affected, indicating that infusion of that volume was not
responsible for any change of the arterial pressure. The time
profile of changes in blood pressure after different doses of ME
infusion into freshly prepared rats were shown in Fig. 4. Within the
first minute after ME, there were severe drops in mean arterial
blood pressure which was quite. typical of a distribution phenomenon.
It was followed by a gradual rise of blood pressure towards normal.
The time required for the blood pressure to return to normal was
dependent on the dose of ME used.
When 0.2 ml Krebs-Ringer was injected into the isolated
perfused heart, no change in heart beat and contractile force was
378 14 224 25 389 21 401 28 391 24
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observed, indicating that injection of that volume was not
responsible for any changes in heart rate and contractile force of
the isolated perfused heart. There was no significant decrease in
heart beat except in the first two minutes after ME administration
(25 mg/ml) as shown in Figure 5. No change in contractile force of
the isolated perfused heart was detected at the same time (Fig-5).
When 25 mg of ME in 1 ml was infused into a rat over a longer
period of time (15 minutes), the change in blood pressure was
minimal (from 116+ 3 to 111+ 4 mm Hg). However, there was a
substantial decrease in inulin clearance (Fig. 6). From our control
experiments, fluctuation of blood pressure within this magnitude did
not affect the iriulin clearance significantly.
2.3 Discussion
The quality of Pleurotus sajor-caju used in this study was well
defined and maintained. Therefore heterogeneity due to genetic
variation and different stages in its life' cycle could be minimized.
The yield of ME preparation was 3.42%. When it was administered
intravenously into anaesthetized rats it induced a depressor
effect in a dose dependent manner. However, the immediate
'hypotensive effect might be due to the vasoactive ions present in
the aqueous extract. For example, potassium and magnesium ions are
known to have a vasodilating effect (51, 52), while calcium ions can
lead to vasoconstriction (53). Reconstituted electrolyte solutions
with simulated cation composition of ME caused a transient pressor
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effect instead of depressor effect. Therefore, any depressor effect
of ME is unlikely due to the major electrolytes in it.
Tachyphylaxis was observed with decreasing hypotensive effect
when ME was repeatedly infused into the same rat. In order to avoid
such complication, each freshly prepared rat was tested with only a
single dose of ME. Infusion of ME produced a dose dependent decrease
in systemic blood pressure. It was neither due_ to the infused volume
nor its major electroyte content. Therefore, it is believed that
active ingredients might be present in the ME which is responsible
for its hypotensive effect.
Arterial blood pressure can be affected by changes in cardiac
output or total peripheral resistance. The results of both in vitro
and in vivo suggest that the long lasting hypotensive action of ME
is unlikely due to a direct action on the heart. Heart rate was only
significantly reduced in the first minute by ME (25 mg/ml/min) when
given intravenously. Studies with Langendorff. isolated heart
perfusion preparation, in which the local concentration of ME within
the heart was much higher during infusion compared to the in vivo
system, indicated that heart rate was significantly reduced for two
minutes only even though the infusion rate (2.4 ml/min) was greater
than that (1 ml/min) of in vivo system. Reduction of heart rate in
the isolated heart preparation may just be the direct action of
elevated potassium ion concentration due to.injected ME (51). The
disturbance on heart rate lasted only for a few minutes but the
hypotensive effect lasted for more than half an hour. Thus, the
transient'reduction of heart rate cannot account for the hypotensive
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action of ME. Langendorff isolated heart preparation also indicated
that ME did not alter the contractile force of heart significantly.
Therefore, reduction in the strength of cardiac contraction is
unlikely to be an efferent limb of ME in reducing the arterial blood
pressure. Further study is required in order to elucidate the
mechanism of ME in lowering the arterial blood pressure.
Reflex tachycardia was not observed in the rats, a plausible
explanation could be due to a transient disturbance in electrolyte
balance. The heart rate rose back to the control value but was
unable to increase much further. Moreover, the variation in heart
rate after ME infusion was much higher than control (as reflected by
the SEM), which made it statistically difficult to detect a
relatively small change in heart rate.
Under normal physiological conditions, the GFR is autoregulated
within a certain range of systemic blood pressure (54). Decrease of
blood pressure outside the range will decrease the GFR and vice
versa. ME has a depressor effect on the blood pressure and it is'not
surprising to observe a decrease in GFR after ME administration.
However, when ME was infused over a longer period of time so that
the change in the systemic pressure was minimal, a significant fall
in GFR was still observed. This demonstrates that the fall of GFR is
not related to the change in the systemic pressure.
This study confirms the pharmacological effects of an aqueous
extract (ME) of Pleurotus sajor-caju. It has a dose dependent
17
hypotensive effect in anaesthetized rats which is unrelated to its
major electrolyte content. It also causes a decrease in GFR of the
rats even after two hours of administration. These two criteria
would then be used as two bioassay systems in identifying the active
ingredients involved during the subsequent steps of purification.
There is no idea of how many active ingredients present in the ME,
or whether the hypotensive effect and renal effect are due to the
same component. In the next three chapters, attempts would be given
to elucidate the biochemical nature of the active ingredients and

















A 2A 4A 8A 16A
Fig. 2 The effects of reconstituted electrolyte solutions
on systolic , diastolic and mean blood
pressure of rats. '4A' represents the-dose with
the cation composition which is equivalent to 25
mg of ME in 1 ml of distilled water
Values are expressed as mean+ SEM (n=5).
Statistical analysis was performed by t-test. All
doses of electrolyte except 'A' caused a
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Fig. 3 The effects of different doses of ME on systolic LL11,
diastolic , and mean blood pressure in rats.
Values are expressed as mean SEM (n=5).
Statistical analysis was performed by Duncan's
test (p<0.05). (NS= not significant)
NS











0 10 20 30
Time (min)
Fig. 4 Time profile of the effects of 12.5 mg/mi u,
25 mg/ml 50 mg/ml and 100 mg/ml of ME on
the decrease in mean blood pressure of rats.
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Fig. 5 Time profile of the effects of ME on the heart rate
0 and relative contractile force of Langendorff
isolated perfused heart. The initial heart rate
was 218+ 21 beat/min. Values are expressed as
mean+ SEM (n=6). Statistical analysis was
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Fig. 6 The effect of saline (control) and ME (25 mg/ml)
infusion on GFR of rats. The initial mean GFR were
3.18+ 0.25 and 3.06+ 0.22 ml/min respectively.
Values are expressed as mean+ SEM (n=8).











The crude aqueous extract (ME) from Pleurotus sajor-caju was
ascertained to be capable of lowering arterial blood pressure and
GFR in rats when given intravenously. The results and methods used
in the subsequent steps of purification would be reported in this
chapter. Criteria of identifying the active ingredients in different
purified fractions were: (i) the lowering of arterial blood
pressure and (ii) decrease in GFR. The methods of these bioassays
had been described in the previous chapter. The mushroom
preparations described in this chapter were extracted with boiling
water since mushrooms are usually cooked before consumption.
Different approaches were attempted to identify the nature and size
of the active ingredients involved.
3.2 Materials and Methods
3.2.1 Preparation of different mushroom extracts
Pleurotus sajor-caju was homogenized with distilled water at
the ratio of 80 g mushroom to 250 ml in a blender for five minutes.
It was followed by keeping the homogenized mushroom suspension in a
100 °C water bath for 30 minutes with stirring. Then the suspension
was shaken and 'centrifuged as described before. One third of the
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supernatant was 1yophilizea ana the proaucz was assigneu as DriZ. 111e
remaining two-third was subjected to ultrafiltration through a PM-10
membrane (MW10,000) with nitrogen in a Diaoflo Cell (Amicon). Half
of the ultrafiltrate was lyophilized and the product was assigned as
BF. The other half was passed through a mixed bed resin (AG501X8,
Biorad) for deionization. The eluent was lyophilized and the product
assigned as BFR. Sodium, potassium, calcium and magnesium ion
concentrations in each preparation were determined as described
previously.. The different preparations of mushroom extracts were
then bioassayed in rats (62.5 mg/kg).
3.2.2 Protein precipitation from mushroom extract BF
Saturated ammonium sulphate was used to precipitate protein
from mushroom extract preparation BF. The process of precipitation
was carried out in cold for 12 hours. Ratio of mushroom extract to
saturated ammonium sulphate is 50 mg to one ml. The precipitate was
collected by centrifugation and redissolved in normal saline for
bioassay (125 mg/kg).
3.2.3 Gel-filtration chromatography of mushroom extract BF
Mushroom extract preparation BF (25 mg/20 ,u1) was applied to a
Sephadex G-25 column (1.3 X 76cm) and eluted with a buffer (1 mM
phosphate ,0.2% saline) at pH 7.0. The rate of elution was 0.7 ml/
min. The absorbance of eluent at 280 nm was continuously monitored
by a flow cell (Single Path Monitor UV-1, Pharmacia). The eluent
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corresponding to different absorbance peaks were separately
collected and lyophilized. The biological activities of different
fractions were then assayed (87.5 mg/kg).
3.2.4 Effect of trypsin on the biological activities of
mushroom extract BF
Trypsin (Type III, Sigma) was usea to aigest zne prvtielu u.L
mushroom extract BF. 250 mg of BF was dissolved in.10 ml of 1%
ammonium bicarbonate solution. 7 mg of trypsin was dissolved in 200
)j1 of 1 mM hydrochloric acid. The dissolved trypsin was then mixed
with the mushroom solution and incubated at 37°C for 4 hours. There
was continuous.shaking during incubation. To control for possible
inactivation of BF activities due to the process of incubation,
another preparation without trypsin was also prepared and incubated
in' exactly the same way. After incubation, trypsin was rapidly
removed by ultrafiltration with microconcentrators (Centricon-10,
Amicon). The molecular weight cutoff of Centricon-10 is 10,000 and
the driving force is derived from centrifugation. This preparation
would then be tested at a dose of 65 mg/kg.
3.2.5 Total protein determination of mushroom extracts
A modified Lowry's method (55) was used to determine the total
protein content of different mushroom extract preparations. The
method was summarized as follows:
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1 ml sample or standard BSA( Bovine Serum Albumin)
containing 20-100 pg protein
Add 0.9 ml Solution A
Warm at 50 °C for 10 min.
Cool to room temperature
+ 0.1 ml Solution B
Stand at room temperature for at least 10 min.
Force in rapidly 3 ml Solution C
Warm at 50 °C for 10 min.
e
Cool to room temperature
Read absorbance at 650 nm
Solution A: 2 g potassium sodium tartrate and 100 g
sodium carbonate are dissolved in 500 ml
1M sodium hydroxide with water to 1 litre.
Solution B 2 g potassium sodium tartrate and 1 g
pentahydrated copper sulphate are
dissolved in 90 ml water and 10 ml 1M
sodium hydroxide is added.
Solution C: I volume Folin-Ciocalteu's phenol reagent
is diluted with 15 volume of water. This
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should be prepared fresh.
3.2.6 Sodium Dodecyl Sulphate-Polyacrylamide Gel
Electrophoresis (SDS-PAGE)
SDS-PAGE was used to estimate the molecular weight of proteins
within the purified fractions as well as to assess their
homogeneity. The system used was specifically designed for the
separation of peptides within the molecular weight range 1,000-
10,000 (56)-. Electrophoresis was carried out on a vertical slab-gel
with dimension of 0.1 X 10 X 12cm( vertical electrophoresis unit,
Hoefer). The composition of buffers and gels used for SDS-PAGE was
shown as follows (57):
CompositionPH
0.1 M Phosphoric acid6.8Both reservoir buffers
0.1% SDS
Tris added to adjust pH
0.01 M phosphoric acid6.8Sample buffer




0.8 M Phosphoric acid6.8Gel buffer
Tris added to adjust pH
0.8 g SDS
0.6 ml TEMED
water to 100 ml
6.25 g acrylamide6.8Running gel
0.625 g Bis
24.20 g urea
6.25 ml gel buffer
water to 50 ml
0.035 g ammonium per-
sulphate
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The composition of stacking gel was a four-folded dilution or
running gel. Sperm whale myoglobin (MW 17,200 ,Schwarz/Mann) and
bacitracin (MW 1,480 Sigma) were used as protein standards. Samples
or standards were dissolved (2 mg/ml) in 1% SDS, 8M urea, 1%
mercaptoethanol, and 0.01M phosphoric acid adjusted to pH 6.8 with
Tris. The solution was then heated for 10 min at 60°C, and stored
overnight at room temperature prior to electrophoresis. Equal volume
of sample and bromophenol blue solution were-mixed and 50 ,Z1 of the
mixture was then applied into the well of a polyacrylamide slab-gel.
The bromophenol blue solution was composed of 0.02% bromophenol blue
in 40% sucrose, 0.1% SDS, and 0.1 M phosphoric acid at pH 6.E
adjusted by Tris. Samples were subjected to electrophoresis towardE
the anode at a constant current of 20 mA for 14 to 16 hours. The gel
was then stained for protein.
For staining, gels were immersed for 2 hours in a solution
containing 1.25 g Coomassie Brilliant Blue, 454 ml 50% methanol,
and 46 ml glacial acetic acid prefiltered through Whatman No. 1
paper. The staining solution was decanted and gels were rinsed once
with water before immersion in the destaining solution. The
destaining solution contains 75 ml acetic acid, 250 ml methanol, and
675 ml water. Destaining was completed by changing the destaining
solution until the gel became transparent.
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3.2.7 Summary of experimental procedures
mushroom+ alstliiea Water









trypsinized BF protein precipitatE
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3.3 Results
The yield of BME, BF and BFR was 3.58+ 0.58 g%, 3.04+ 0.63
g% and 2.88+ 0.33 g% respectively. The profiles of hypotensive
action of these three preparations were shown in Figure 7. The
recovery was-most rapid in BFR, while the hypotensive action of BME
and BF were of similar potency. The effects of BME and BF on GFR
were shown in Figure 8. Both of them could reduce the GFR
significantly even after three hours of administration.
The precipitate from BF by saturated ammonium sulphate showed
both the activities of lowering arterial blood pressure and reducing
GFR in rats (Fig.9a and 9b). No biological activities were detected
in the supernatent. Protein assay indicated that about 67% of the
total protein content was found in the precipitate while the
remaining protein was still dissolved in the supernatant. When
trypsinized -BF was tested for its hypotensive activity, its potency
was reduced'as compared to that of the control (Fig. 10).
The eluent absorbance profile (Fig.11)_of BF from the Sephadex
G-25 column was divided into four fractions, namely, Fo, F1, F2 and
F3. All absorbance peaks appeared after the void volume. Bioassays
indicated that Fl was the only fraction active in lowering arterial
blood pressure (Fig-7), and also was the only fraction active in
reducing GFR (Fig.8). The electrophoretic pattern revealed one major
band from Fl (Fig. 12). Its molecular weight was estimated to be
between 1,500 and 5,000.
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The cations composition of 25 mg of different mushroom extract
preparations in 1 ml of distilled water were shown as follows:
Cation concentration (mM)
Ca++Mg++K+Na+
0.51 t 0.0812± 160 ± 3ME 50± 4
7.58 ± 3.81 0.09 ± 0.1211.15 ± 3.81BME 0.65 0.30
9.61 ± 1.92 0.13 ± 0.040.50± 0.13BF 13.12 3.19
0.19± 0.12 0.13 ±0.040.18±0.140BFR
6.53+ 3.33 0.40± 0.07F1 202.39± 15.68 10.30 t 7.07
values are expressed as mean± 5m
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The total protein content, specific activity in lowering
arterial blood pressure( change in blood pressure at the first
minute/ protein content) and specific activity in reducing GFR
(change of GFR at 45 minutes after administration/ protein
content) of different mushroom extract preparations were shown as
follows:
Specific Activity of
lowering 'BP lowering GFRProtein content
(ug/mg of sample) mm (Hg/mg) (change/mg)
8.7+ 2.17.5+ 1.2209.8+ 14.5'ME
12.9+ 0.512.8+ 1.9125.8+ 8.1BME
9.1+ 2.816.6+ 2.8BF 115.1+ 9.8
15.8+ 2.078.8+ 15.7BFR
7.1+ 12.215.4+ 1.8F1 68.0+ 4.7
values are expressed as mean+ SEP
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3.4 Discussion
The new mushroom preparations BME and BF displayed both the
hypotensive action and renal activities like the ME. It means that
the active ingredients involved are heat stable. Since BF has passed
through a PM-10 membrane which is permeable only to molecules
smaller than 10,000 and still retains the activities. This strongly
suggests that the active component is of a molecular. weight less
than 10,000.
Precipitate from BF with saturated ammonium sulphate is active
in lowering arterial blood pressure and GFR. Treatment with 10%
perchloric acid abolishes all the biological activities of BF. These
evidences suggest that the active ingredients involved are protein
in nature, since perchloric acid is a strong protein denaturing
agent and ammonium sulphate is a very mild one. However, there is no
idea about the nature of these proteins.
Trypsin treatment of BF does not- abolish but reduces its
hypotensive potency. The hypotensive action of trypsinized BF is
reduced to about 50-70% of the control. Trypsin is a protease
specifically to cleave on the C-terminal side of lysine and arginine
residues. The hypotensive action of trypsinized BF may be due to
incomplete digestion, since many peptides are resistant to heat and
peptidases.
During the fractionation with gel-filtration chromatography,
four absorbance peaks were detected. Biological activities were
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detected only in the second peak (Fl). SDS electrophoresis of F1
revealed only one protein band. Since the molecular exclusion limit
of Sephadex G-25 is 5,000 and the position of the protein band lies
above bacitracin (MW 1,480), thus the molecular weight of protein is
suggested to be between 1,500 and 5,000. However, the purity of F1
is still doubtful because three very faint protein bands above F1
are also observed. These four faint bands are very prominent when BF
instead of. F1 is subjected to electrophoresis. Thus, -these bands
may be the impurities during the collection of eluent.
The specific activity in lowering arterial blood pressure
varies in different preparations. Specific activity increases from
7.48± 1.23 to 12.87± 1.93 mmHg/mg when the extract is prepared
with boiling. Ultrafiltration further increases the specific
activity to 16.62+ 2.75 mmHg/mg but fractionation with Sephadex
does not increase the specific activity. It means the gel-filtration
is not very effective'in fractionating the active ingradients from
the impurities. Deionization does not change the specific activity
significantly as predicted. It is because the hypotensive action of
the extract is not due to its electrolyte content. The specific
activity of lowering GFR in different extract preparations has a
similar trend, except that ultrafiltration does not further increase
the specific activity. However, no inference can be made because
there is no idea about the dose-response relationship in its renal
activity.
The total protein content is highest in ME. Protein content of
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BME is less than ME because extraction with boiling will denature a
certain amount of protein which is then discarded after
centrifugation. Protein content of BF is further reduced because of
the removal of large protein molecules during ultrafiltration. BFR
has the lowest protein content amongst the four preparations
(ME,BME,BF,BFR) and is believed to be due to the non-specific
binding of protein to the resin. The protein content of F1 depends
on the amount of buffer lyophilized.
Simulated electroyte solution of ME has demonstrated that.
electrolytes cannot account for its hypotensive action as mentioned
in Chapter II. The cations content of BME and BF is even less than
ME, and thus it is logical to assume that these cations in BME and
BF also do not contribute to any physiological activities. Lowered
electrolyte content can be attributed to the co-precipitation of
electrolytes with coagulated proteins. Although mixed bed resins can
nearly exchange all cations and anions with hydrogen and hydroxide
ions, BFR is still hypotensive. It means that the vasoactivity of
mushroom extracts is not related to any electrolytes at all, but
some unidentified factors. The sodium ion content of F1 is much
higher than other preparations because the eluent is a phosphate
buffered saline. Control experiments with lyophilized phosphate
.buffered saline indicated that the unusually high level of
,electrolytes at the testing dose of F1 does not associate with any
observable biological activities.
In summary, it is suggested that the active ingredient from the
mushroom extract in lowering arterial blood pressure and GFR of rat
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is likely to be a peptide. The peptide involved is heat stable,
partially susceptible to trypsin digestion and its molecular weight
is estimated to be between 1,500 and 5,000. In the subsequent
chapters. F1 would be used as the most purified extract available to
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Fig. 7 Time profile of the effects of BME BF
BFR and F1 on the mean blood pressure of
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Fig. 8 The effects of saline (control) F1 BF
and BME infusion on GFR of rats. The initial
GFR were 3.18±0.27, 3.18±0.22, 3.07± 0.38,
and 3.71± 0.38 ml/min respectively. Values are
expressed as mean+ SEM (n=6). Statistical analysis
was performed by t-test. After mushroom extracts
infusion, the GFR decreased significantly
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Fig. 9a Time profile of the effect of protein precipitate
from BF on the mean blood pressure of rats. The
initial mean blood pressure was 116.60± 6.41
mmHg. Values are expressed as mean± SEM
(n=6). Statistical analysis was performed by t-
test. The decrease in blood pressure is significant
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Fig. 9b Effect of protein precipitate from BF on GFR of
rats. The initial GFR was 3.13 0.17 ml/min.
Values are expressed as mean SEM (n=6).
Statistical analysis was-performed by t-test. All
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Fig. 10 Time profile of the effects of trypsinized BY
and the control on the mean blood pressure of
rats. The initial mean blood pressure were 112±
5.98 and 118.40± 4.05 mmHg respectively. Values
are expressed as mean±SEM (n=6). Statistical
analysis was performed by t-test. The decrease in
blood pressure are significant (p0.05) except
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Fig.11 Elution profile of mushroom extract BF on Sephadex
G-25. Three mg of protein in 50 j1 was applied to










Fig. 12 SDS-polyacrylamide gel electrophoresis of BF and
Fl. Myoglobin (M) and bacitracin (B) were used
as protein markers, their molecular weight are





In Chapter II, the hypotensive action of ME had been confirmed.
The effect was not due to its direct action on the heart. The
transient reduction of heart rate in the first few minutes after ME
infusion could not account for the long lasting hypotensive action.
Furthermore, the Langendorff isolated heart perfusion study revealed
that ME did not alter the strength of contraction significantly. In
this chapter, attempts were made to delineate the action of ME on
the cardiovascular system by using various blockers which were known
to affect blood pressure. The possible involvement of alpha-
adrenoceptor, beta-adrenoceptor, muscarinic receptor, histamine-1,
histamine-2. receptors and renin-angiotensin system were'studied. F1
was used throughout- the study as the most purified fraction
available at a dose 87.5 mg/kg (equivalent to 4.5 mg protein/kg).
4.2 Materials and Methods
Rats (350-400 g) were anaesthetized and the carotid artery and
jugular vein of each rat were cannulated as described previously.
All fuilds were given intravenously via the jugular vein. Agonists
and antagonists were dissolved in normal saline and given in bolus
injection of 0.2 ml except the converting enzyme inhibitor. The
agonist was given before and after the antagonist to ensure an
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effective blockade and then followed by the infusion of Fl. The
changes in arterial blood pressure and heart rate were monitored for
30 minutes.
4.2.1 Alpha-adrenoceptor
The effect of alpha-adrenoceptor blockade on the hypotensive
effect of F1 was investigated. The agonist used was methoxamine
(Sigma) while the antagonist was phentolamine (Sigma). An effective
dose. of methoxamine (50 )ig/kg) was injected intravenously to observe
the pressor response and then followed by a dose of phentolamine
(2 mg/kg). As soon as the arterial blood pressure became steady, the
same dose of methoxamine was given again to challenge the alpha-
blockade. When alpha-blockade was confirmed, a test dose of F1 was
then given immediately.
4.2.2 Beta-adrenoceptor
The agonist and antagonist used were isoproterenol (Sigma) and
propranolol (Sigma) respectively. Isoproterenol (0.2 pg/kg) was
injected to observe its vasodepressor effect. A blocking dose of
propranolol (2 mg/kg) was then followed and the beta-blockade was




Acetylcholine (Sigma) and atropine (Sigma) were used as the
agonist and antagonist respectively. Acetylcholine at a dose of 2
,ug/kg was injected to observe its hypotensive response before the
muscarinic blockade. An effective blocking dose (2 mg/kg) of
atropine was then administered and the effectiveness of blockade was
vertified by the same dose of acetylcholine. A test dose of F1 was
then followed.
4.2.4 Histamine receptors
Pyrilamine (Sigma) and cimetidine (Sigma), a H1 and H2 receptor
blocker respectively, were injected together at a dose of 10 mg/kg
each. The blockade was then examined by injecting histamine (Sigma)
at a dose of 2 ug/kg. A test dose of F1 was immediately followed
after the blockade was vertified.
4.2.5 Renin-angiotensin system
The possible interaction of the hypotensive action of mushroom
extract with the renin-angiotensin system was studied by using a
converting enzyme inhibitor Captopril (SQ 14,225, Squibb).
Captopril (10 pg/min/kg) was infused into the rat in 0.9% saline
at a rate of 0.078 ml/min. Its effectiveness in inhibiting the
conversion of angiotensin I to angiotensin II was tested by
injecting angiotensin I (40 ng/kg) after 30 minutes captopril
infusion. When blockade of conversion was ensured by a lack of
pressor response after angiotensinl administration, infusion was
stopped and a test dose of Fl was administered.
4.3 Result:
Significant reduction in heart rate could only De rouna in tine
first minute after the administration of F1 in all treatments. No
reflex tachycardia was observed in all cases. The time profile of
heart rate (beat/min) in rats pretreated with different
pharmacological antagonists before and at various times after the
administration of F1 were tabulated as follows:
Time after Fl (min)
15 3010 5
386 22control 392t18' 342± 2Z X62± 16 387±18
375± 16 399±28 399± 13alpha- 37919 317±12
11
315 14 263 20 295±21 307± 14 311± 17beta-
405± 23cholin. 389± 15 269± 27 377±13 399±21
29516 323± 22274± 15 292±10 271± 9H1/H2
396± 11CET 355 20 401±8 401±9397±11
cholin.= cholinergic, CEI= converting enzyme inhibitor
all values are expressed as mean± SEM
p<0.05
In this study, phentolamine was used as the alpha-adrenoceptor
blocker. Effectiveness of phentolamine blockade was demonstrated by
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administration of an alpha-agonist methoxamine. The pressor effect
of methoxamine reduced from 45.35+ 1.24 to 2.35+ 0.91 mmHg after
the blockade. Hypotensive action of F1 was not affected after the
alpha-adrenoceptor was blocked (Fig-13).
Propanolol was used as a beta-adrenoceptor blocker. The
depressor effect of the beta-agonist isoproterenol diminished from
20.00± 4.43 to 8.12+ 1.96 mmHg after propanolol blockade. However,
the beta-blockade did not seem to impair the hypotensive action of
F1 (Fig. 14).
Atropine was used as a muscarinic receptor blocker.
Effectiveness of atropine blockade was demonstrated by
administration of the agonist acetylcholine. The depressor effect of
acetylcholine decreased from 45.16± 2.12 to 4.33± 5.33 mmHg. When
muscarinic receptor blockade was confirmed, infusion of F1 was still
able to elicit a reduction in blood pressure (Fig. 15).
Histamine-1 and histamine-2 receptors blockade abolished the
hypotensive action of histamine completely.. However, a persistent
reduction of arterial blood pressure was still observed after F1
(Fig. 16).
The converting enzyme inhibitor (Captopril) decreased the
pressor effect of angiotensin I from 21.30± 2.03 to 13.70± 2.40 mm
Hg. Inhibition of the converting enzyme not only reduced the
magnitude, but also the duration of hypotensive action of F1 (Fig.




Various receptors are known to affect blood pressure (58). If
the effect of F1 is mediated through a specific receptor, blockade
of such receptor with the antagonist will abolish the effect of Fl.
From the present study, it is evident that the hypotensive action of
F1 is not mediated by alpha-adrenoceptor, beta-adrenoceptor and
muscarinic receptor. Blockade on these receptors do not affect the
hypotensive action of Fl.
It is not surprising to find that direct administration of
foreign substances into the blood stream may stimulate histamine
release from mast cells and basophils (59). Massive histamine
release can.induce an anaphylactic shock characterized by a decrease
in systemic blood pressure. The hypotensive action of F1 is unlikely
due to this nonspecific stimulation of histamine release, because
blockade of H1 and H2 receptors does not attenuate its effect.
Captopril (D-3-mercapto-2=methylpropanoyl-l-proline) is an oral
competitive inhibitor of the angiotensin-converting enzyme (60). The
enzyme is reponsible for conversion of inactive angiotensin I to the
potent vasopressor angiotensin II and the degradation of
vasodilating peptide bradykinin. Amongst all of the pharmacological
antagonist studies, only captopril can significantly reduce both
the magnitude and the duration of the hypotensive action of Fl. It
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suggests that the hypotensive action oz ri may oe meulduCU uy
interfering with the angiotensin converting enzyme. The inhibitory
effect of F1 in the conversion of angiotensin I to angiotensin II
was confirmed in another experiment, in which the pressor effect of
angiotensin I (40 ng/kg) in rat was significantly reduced from 33.50
+ 5.56 to 27.25+ 6.15 mmHg after 15 minutes of F1 administration
(t-test, p0.05, n=6).
There is no doubt that captopril (angiotensin converting enzyme
inhibitor) causes a decrease in total peripheral resistance and thus
lowering the blood pressure. However, captopril is active not only
in animal models with high plasma renin activity, but also those
with normal or low plasma renin activity. The unexpected efficacy of
captopril in virtually all forms of hypertension has led to many
speculations concerning its mechanism of action (61). These
mechanisms might originate from effects of captopril such as
inhibition of local angiotensin II generation in different tissues,
including central nervous system (62) an increase in local renal
and circulating levels of kinins (63) an increase in the renal
production of prostaglandin PGE2 (64) and an increase in urinary
sodium output (65). All of which might account for the decrease in
total peripheral resistance caused by captopril in hypertension.
Since the efficiency of captopril in lowering blood pressure is
highly correlated with the plasma renin activity (60), inhibition of
angiotensin converting enzyme is probably of major importance to
captopril's blood pressure-lowering effect. It is not clear what
aspect of angiotensin-converting enzyme inhibition is of primary
importance.
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In summary, the pharmacological antagonist studies reveal
that the hypotensive action of F1 is not mediated through the
alpha-adrenoceptor, beta-adrenoceptor, muscarinic receptor and
histamine receptors. Inhibition of the angiotensin converting enzyme
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Fig-13 Time profile of the effects of F1 on the mean
blood. pressure of rats after alpha-adrenoceptor
blockade (with blocker without blocker).
The initial mean blood pressure of rats was 125.50
± 4.31 mmHg. It fell to 102.00± 4.82 mmHg after
administration of the blocker. Values are
expressed as mean± SEM (n=8). Statistical analysis
was performed by t-test. The decrease in blood
pressure is significant (p0.05) except labelled
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Fig. 14 Time profile of the effects of F1 on mean blood
pressure of rats after beta-adrenoceptor blockade
(with blocker 0 without blocker). The
initial mean blood pressure of rats was 125.50
4.31 mmHg. It fell to 101.00+ 7.32 mmHg after
administration of blocker. Values are expressed as
mean+ SEM (n=8). Statistical analysis was
performed by t-test. The decrease in blood
pressure is significant (p<0.05) except labelled
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Fig. 15 Time profile of the effects of F1 on mean blood
pressure of rats after muscarinic receptor
blockade (with blocker®, without blocker).
The initial mean blood pressure of rats was 125.50
4.31 mmHg. It fell to 112.25+ 5.10 mmHg after
administration. of the blocker. Values are
expressed as mean+ SEM (n=8). Statistical analysiE
was performed by t-test. The decrease in blood
pressure is significant (p0.05) except labelled
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Fig. 16 Time profile of the effects of F1 on the mean
blood pressure of rats after histamine-1 and
histamine-2 receptors blockade (with blocker
without blocker). The initial mean blood
pressure of rats was 125.5+ 4.31 mmHg. It fell
to 101.25+ 4.02 mmHg after administration of the
blocker. Values are expressed as mean+ SEM (n=8).
Statistic analysis was performed by t-test. The
decrease in blood pressure is significant (p0.05)
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Fig. 17 Time profile of the effects of F1 on the mean
blood pressure of rats after angiotensin
converting enzyme inhibition by captopril (with
captopril, without captopril). The initial
mean blood pressure of rats was 125.50+
4.82 mmHg. It fell to 121.25+ 5.31 mm Hg after
captopril infusion. Values are expressed as mean+
SEM (n=8). Statistic analysis was performed by t-
test. The decrease in blood pressure is











The crude mushroom extract (ME) was found to lower glomerular
filtration rate (GFR) in rat when given intravenously. This
physiological effect was still observed in the purified fraction Fl.
In this chapter, the renal effect of F1 was further characterized by
monitoring its action on GFR, renal plasma flow (RPF) and filtration
fraction (FF). The rate of urinary sodium excretion and fractional
sodium excretion were measured in order to investigate its tubular
action. The role of captopril in this aspect was also investigated.
It. is believed that the hypotensive effect of F1 involves renin-
angiotensin system, which also plays an important role in the
regulation of renal hemodynamics (60).
5.2 Materials and Methods
5.2.1 General procedures
Male Spraque-Dawley rats (350-400 g) were anaesthetized with
sodium pentobarbital (60 mg/kg) and polyethylene catheters (PE-50)
were placed in the left carotid artery and in the right jugular and
femoral vein. The bladder catheter consisted of polyethylene tubing
(PE-240) with a flanged end placed in the bladder. The effects of F1
on renal hemodynamics were studied by measuring GFR and RPF
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simultaneously. GFR was measured with tritiated-inulin as aescripeu
previously, while the clearance of sodium para-aminohippurate (PAH)
was used to estimate the RPF (66).
A priming dose of tritiated-inulin (5 )uCi) and PAH k4.b mg,
Sigma) in 0.75 ml normal saline was injected via the jugular vein,
followed by a maintenance dose (0.082 uCi/min of inulin, 0.48 mg/min
of PAH) infused at a rate of 0.078 ml/min saline. Urine samples were
collected at intervals of 45 minutes via' the bladder catheter.
Arterial blood samples were collected at the midpoint of each
period. After two control periods, one ml of F1 solution with a
concentration 35 mg/ml (1.8 mg protein/ml) was infused via the
femoral vein over 15 minutes. Arterial pressure was measured
throughout the.experiment except during blood sampling. In control
experiment. normal saline was infused instead of F1 solution.
PAH concentrations of plasma and urine were cte-terminea
colorimetrically with chemical method (67). Tritiated-inulin
concentrations of plasma and urine were measured by liquid
scintillation counting. Sodium content of plasma and urine were
determined with a Corning 435 flame photometer. Filtration fraction
(FF) was calculated as the ratio of inulin/ PAH clearance X 100%.
Fractional excretion of Na was calculated as Na excretion/ Na
filtration rate X 100%.
5.2.2 Animal studies
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Rats were divided into 4 groups. Each consisted of 8 rats. The
investigation period lasted for 270 minutes (i.e. 6 clearance
periods). One ml of fluid (F1 solution or saline) was infused into
each rat over 15 minutes after two clearance, periods (90 minutes).
Group I was the control group. Inulin and PAH in saline were
infused continuously over the experiment. One ml of saline was
infused into the rat after two clearance periods. In Group II,
animals were treated identically except one ml of FT solution was
infused instead of saline.
In Group III, captopril (10 )ug/min/kg) was infused
concomitantly with inulin and PAH. One ml of saline was then
administered over 15 minutes after two clearance periods. In Group
IV, the animals were treated identically to that of Group III but F1
solution instead of saline was administered.
5.3. Results
Infusion of saline, F1, or captopril did not affect the blood
pressure significantly. It remained quite constant throughout the
experiment.
Rats in the control group (Group I) were infused with saline
instead of F1. Both the GFR and RPF remained constant throughout the
extire experimental period (Fig.18,19).
Infusion of F1 over 15 minutes to normal rats (Group II)
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consistently decreased the GFR (Fig. 18). Renal plasma flow was not
different from the control value throughout the experiment except
that a lower value was measured during the first 45 minutes after F1
infusion (Fig. 19). Filtration fraction decreased after F1 infusion
(Fig.20).
In the rats continuously infused with captopril (Group III),
both the GFR as well as RPF were above the'control level with no
change in the filtration 'fraction. In another group of rats
receiving the same amount of captopril (Group IV), infusion of F1
was unable to lower the GFR and RPF (Fig. 18,19). The filtration
fraction was again not changed in these rats (Fig. 20).
All the rats received a saline load and therefore an increase
in urinary sodium excretion was observed. The change in urinary
sodium excretory rate did not differ from one group to another (Fig.
21). When the GFR was taken into account and the urinary sodium
excretory rate expressed as fractional sodium excretion, a similar
pattern was obtained (Fig. 22). This suggested that neither F1 nor
captopril affected urinary sodium excretion significantly.
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The urinary flow rate of the four groups of rats at different
clearance period was tubulated as follows:
Urinary Flow Rate( X 0.01 ml/min)
Group IVGroup IIIGroup IIGroup IPeriod
2.94±0.47S-T(± u. 452.17± 0.20 2.76± 0.621
4.35± 0.806.57± 0.884.90± 0.933.46± 0.752
5.70± 0.785.15± 0.616.44±0.973.26± 0.633
7.18± 0.144.53± 0.465.07± 0.563.11± 0.484
3.82± 0.604.27± 0.64 4.700.762.75±0.205
2.87± 0.442.72± 0.472.34± 0.342.08± 0.336
values are expressed as mean+ SEM
The urinary flow rate of all rats were of similar pattern. There




Data from the control rats (Group I) inaicates tnat
experimental manipulation does not lead to any significant change in
the renal hemodynamics throughout the investigation period. The GFR,
RPF and FF all remain in a more or less steady value. Continuous
saline loading induces a gradual rise and then a decline of urinary
sodium excretory rate. It means that urinary sodium excretion has
attained equilibrium under constant infusion. Urinary flow rate
varies in a similar manner because saline infusion induces diuresis
as well as natriuresis until a new equilibrium state is established.
Reduction of GFR after ME infusion has been reported in chapter
II. The decrease is independent of the change in systemic blood
pressure. The renal action of the purified fraction F1 is not
different from ME. Acute renal failure (ARF) induced by heavy metals
(e.g. Hg, Ar, Pt, Bs) and organic solvents (e.g. glycerol,
uranyl acetate) is also associated with drastic decrease in GFR
(68). Thus, it is logical to ask the question whether infusion of F1
does induce acute renal failure.in rats. Despite years of efforts,
the pathophysiology of ARF remains uncertain. Currently there are
two schools of thought with respect to ARF one emphasizes on the
vascular events and the other emphasizes on the tubular events, as
the cause of renal failure.
The vascular theory states that when there is a marked decrease
in renal perfusion pressure or preglomerular vasoconstriction,
glomerular plasma flow and hydrostatic pressure will decrease. If
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the change is large enough, it will lead to a decrease in glomerular
filtration rate and acute renal failure. Decrease in blood supply to
the tubules will lead to ischemia and impairment of tubular
functions. According to this theory, ARF must always be associated
with a decrease in RPF (69). However, the infusion of F1 only causes
a significant reduction of RPF( about 10%) at the first clearance
period. The change of RPF becomes insignificant in the subsequent
periods. Therefore, the decrease of GFR is unlikely due to the
reduction of RPF. Ischemia is also unlikely because 10% reduction
of RPF is still within the physiological range.
The tubular theory suggests that ischemic or toxic insults
produce renal tubular epithelial-cell injury. Such injured
epithelial cells have impaired functions such as 'back-leak' of
tubular fluid, and tubular obstruction due to cellular debris (70).
Tubular damage also impairs sodium reabsorption along the proximal
convoluted tubule or the loop of Henle leading to an increased
sodium delivery to the macula densa thereby activating the renin-
angiotensin system to decrease blood flow and filtration in the
injured nephron (71). According to this theory, ARF is always
associated with increase in fractional sodium excretion as well as
reduced RPF (72). However, there are neither consistent decrease of
RPF nor increase in fractional sodium excretion after infusion of
F1. Therefore, it is reasonable to believe that the reduction of GFR
after F1 is not a consequence of induced ARF.
Although the mechanism of F1 in lowering GFR is not obvious
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from these studies, its possible sites of action may still be
examined. The rate of ultrafiltration for the entire capillary
network of a single glomerulus is given by (73):
SNGFF
where the Single nephron glomerular filtration rate (SNGFR) is
determined by the ultrafiltration coefficient( K f) and the
difference (PUF) between the mean transcapillary hydraulic (AP)-and
oncotic pressure (AID average over the length of the capillary. K f
is the product of effective hydraulic permeability( k) and the
surface area available for filtration( S). The mean transcapillary
hydraulic pressure difference, AP, is equal to the difference
between mean hydraulic pressure within the glomerular capillary
(PGC) and that on the urinary side of the filtering capillary, i.e.,
in Bowman's space (PT) The mean trnasmural* oncotic pressure
difference( 4ll) is equal to the difference between mean oncotic
pressure of the plasma within the glomerulas capillary ('GC), and
that of the filtrate in Bowman's space (11T). Usually the total
protein concentration in. the filtrate is extremely low and
II Tmay be regarded as negligible.
Change in the oncotic pressure due to infusion of F1 is
unlikely because the total amount of protein infused into each rat
is only 1.8 mg. A reasonable urine flow rate excludes the
possibility of.ureteral obstruction, and a normal P is expected.
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The FF is falling after Fl. A falling FF may implicate relative
change in the afferent and efferent arteriole tone. A decrease in
GFR without the company of RPF suggests constriction on the afferent
and dilatation on efferent arterioles. Converting enzyme inhibitor
and angiotensin II both affect the efferent arteriole more than the
afferent arteriole (74). Preferential dilatation of efferent
arterioles by saralasin (an angiotensin II antagonist) was reported
when both the afferent and efferent arterioles were preconstricted
by angiotensin II (75). However, there is yet no substance reported
that can.affect the afferent and efferent arterioles in an opposite
direction. The next possible site of F1 action is a reduction in the
glomerular filtration surface. Contraction of the glomerular
mesangial cell can reduce the surface for ultrafiltration and thus
decrease GFR. Angiotensin II is a possible candidate to mediate this
contraction but it remains to be elucidated (76).
Captopril is well documented to increase RPF by reducing the
renal vascular resistance, and in addition, it can elevate the GFR
to a small extent (77). Elevated RPF and GFR are observed when
captopril is infused continuously into the rats, and infusion of F1
cannot reduce the GFR in these rats. Captopril may counteract the
action of F1 in either dilating the efferent and afferent arterioles
concomitantly or preventing the contraction of glomerular mesangial
cells.
Many organs are capable of maintaining relative constant blood
flow in the face of major changes in perfusion pressure. This
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autoregulation is most efficient in the brain and the kidney (78).
The renal vasculature has a low resting resistance, allowing the
kidney to receive a high rate of blood flow. The high blood flow is
essential to provide the large volume of fluid necessary for
filtration. Because GFR is more directly related to renal excretion
than renal blood flow, it is also reasonable to predict that GFR
would be more precisely regulated than renal blood flow. In most
circumstances, it is true that maintenance of GFR is in the expense
of RPF. However, F1 seems to break this kind of regulation. Its
potential clinical implication will be mentioned in the next
chapter.
In summary, the purified fraction F1 from the edible mushroom
Pleurotus sajor-caju can lower the GFR of rats up to 30% when given
intravenously. Its effect is progressive and lasts at least for
three hours. The decrease in GFR is not due to a decrease in RPF nor
the consequence of tubular damages. Its possible mechanisms of
action are (i) preferential constriction on -the afferent and
efferent arteriole, (ii) a reduction in the filtration surface by
mesangial cell contraction. Continuous infusion of captopril totally
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Time interval (45min)
Fig. 18 Time profile of changes of GFR in different groups
of rats (control, with F1, with captopril
with captopril and F1 0). Fluid infusion (either
saline or F1 solution) started after 90









1 2 3 4 5 6
Time interval (45min)
Fig. 19 Time profile of changes of RPF in different groups
of rats (control, with F1,, with captopril
with captopril and F1 ). Fluid infusion (either
saline or F1 solution) started after 90















1 2 3 4 5 6
Time interval (45min)
Fig. 20 The change of FF in different groups of rats at
different clearance periods (control, with F1,
with captopril with captopril and F1). Fuild
infusion (either saline or F1 solution) started
after two clearance periods (90 minutes) of











Fig. 21 Time profile of changes in fractional Na excretion
of different groups of rats (control, with F1
with captopril and F1). Fluid infusion (either
saline or F1 solution) started-after 90 minutes of











1 2 3 4 5 6
Time interval (45 min)
Fig. 22 Time profile of changes in urinary Na excretory
rate of different groups of rats (control,
with F1, with captopril and F1,). Fluid
infusion (either saline or F1 solution) started
after 90 minutes of equilibration. Values are











Eritadinine from Lent-inus edodes is the only substance reported
to be beneficial to hypertensive patients by lowering the plasma
cholesterol level (40). However, hypercholesterolemia as the primary
cause of hypertension is not very common. Eighty percent of the
hypertensive patients do not have a well defined cause and are
collectively termed as essential hypertension. From the present
study, an aqueous extract from phoenix mushroom can lower the
arterial blood pressure of rat in a dose dependent manner when given
intravenously. The hypotensive effect of this extract is not due to
its electrolyte content. The active ingredient is believed to be a
peptide which is heat stable, partially inactivated by trypsin
digestion and with a molecular weight between 1,500-5,000. Small
polypeptides with biological activities isolated from other edible
mushrooms have been reported (79,80,81,82). For example,
pleurotolysin isolated from Pleurotus ostreatus is a well
characterized polypeptide, which is heat labile and is able to
hemolyse mammalian erythrocytes in vitro (83).
The hypotensive action of the mushroom extract is not mediated
through alpha-adrenoceptor, beta-adrenoceptor, muscarinic and
histamine receptors. Minimal reflex tachycardia is observed and the
heart rate is disturbed only in the first few minutes after its
administration. Its mechanism of action is believed to be
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vasouiiazazlon leaaing to a uecrease of the total peripheral
resistance by inhibiting the angiotensin converting enzyme.
Converting enzyme inhibitors are commonly used as antihypertensive
drug, which have several distinct advantages over conventional
antihypertensive therapy (84). These include: (i) minimal side
effects from the nervous system, (ii) retention of cardiovascular
reflexes to posture, exercise and anaesthesia, (iii) potentiation of
the action of diuretics, and prevention of secondary
hyperaldosteronism and hypokalaemia, (iv) maintenance of renal blood
flow and renal function, (v) active in various types of
hypertension. Hence, the active ingredient in Pleurotus sajor-caju
which lowers systemic blood pressure by inhibiting the converting
enzyme is more appealing than others. The modern converting enzyme
inhibitors are derived from peptidic inhibitors isolated from the
venom of the South American pit viper, Bothrops jaracara (85).
Therefore, it is not surprising to discover a peptide from a
mushroom which can also inhibit the angiotensin converting enzyme.
Purified aqueous extract of Pleurotus sajor-caju is not only
capable of lowering the arterial blood pressure but also reducing
the GFR of rat. The decrease in GFR occurs within 45 minutes after
F1 infusion and lasts at least for another three hours. The decrease
is not related to the change in the systemic blood pressure since
there is no significant change in the blood pressure during and
after the infusion of mushroom extract. Renal hemodynamic studies
indicated that the fall of GFR is not due to a reduction in RPF.
There is no apparent gross tubular damage since the fractional
sodium excretion is comparable to the control.
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As mentioned previously, the GFH is autoregulatea witnin a
certain range of systemic blood pressure at the expense of renal
blood flow (54). The mushroom extract is able to alter the GFR
without affecting the systemic blood pressure and renal blood flow.
Renal hemodynamics can be affected by the intrarenal infusion of a
variety of vasoactive agents such as epinephrine (86), angiotensin
(87), prostaglandins (88), papaverine (89), acetylcholine (90) and
adenosine (91) particularly papaverine which paralyses smooth muscle
and abolishes autoregulation. It is interesting to note that most of
the vasoactive substances are administered through the intrarenal
route in order to avoid severe change in systemic blood pressure.
The mushroom extract is unique in such a way that it can be
administered intravenously without much disturbance on systemic
blood pressure. Its mechanism of action in the renal aspect is not
clear but seems to be independent of its cardiovascular activity.
Preferential constriction on the afferent and efferent arterioles or
a reduction in the glomerular filtration surface' are the two
possible.. mechanisms of action though no direct evidence is
avialable.
In chronic renal disease, the GFR of each surviving nephron is
increased and therefore the workload to the renal tubule. It is
suggested that such an increase in workload might lead to further
loss of renal function and contributes to the progression of the
disease (92). A potential use of this mushroom extract is to keep
the GFR at a low value, hence reducing the workload and prolong the
survival of the nephron.
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In order to further. characterize the mechanism of action of the
mushroom extract, further purification is necessary to identify the
chemical nature of the active ingredient. The possibility of tubular
damage induced by the mushroom extract -shall be explored by
detecting changes of specific markers (e.g. beta-2-microglobulin)
of renal tubular damage (93). Finally, the mechanism of how mushroom
extract induces the fall of -GFR can be further clarified by using
micropuncture technique. More importantly,, the possible benefical
effect of the phoenix mushroom to patients with chronic renal
failure should be investigated.
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